HIV Interactions In Viral Evolution

病毒进化中的艾滋病毒相互作用

基本信息

  • 批准号:
    9769769
  • 负责人:
  • 金额:
    $ 531.78万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-09-01 至 2022-08-31
  • 项目状态:
    已结题

项目摘要

The HIV Interaction in Viral Evolution (HIVE) Center came together a little more than four years ago to understand, at the atomic, biophysical and evolutionary level, the system interdependency of interacting HIV macromolecules and their assemblies which shape the HIV life cycle. To accomplish this goal the proposed program will continue to explore the structural and biophysical interactions of HIV Gag and Gag-Pol polyproteins, capsid, reverse transcriptase, and integrase and their evolutionary relationships. The Center's research focus will also extend to cellular factors that inform the structural and macromolecular dynamics of events in reverse transcription, assembly, and integration. This will include studies on how APOBEC3 proteins suppress reverse transcription, and the role of LEDGF in guiding viral integration and its contribution to latency in conjunction with CPSF6. Studies on HIV drug resistance will tie together a genetic and structural perspective, based on mutational correlations that are due to constraints on protein structural stability and function and which ultimately shape fitness. The depth of the computational strength of the program is centered on expanding structural, biophysical, and viral sequencing findings for developing predictive structural models and small molecule probes targeting viral function. The strength of the Center's biological and computational research will provide insights into the interrelationships of viral and host mechanisms, enabling discovery of new drug targets and therapeutic strategies that may ultimately lead to a cure. The HIVE Center comprises a group of highly collaborative investigators with deep experience in HIV research and well established expertise in structural, biophysical, biochemical, and computational biology, as well as synthetic chemistry, and virology. They will study the mechanistic implications of viral and viral-host macromolecular interactions along with the dynamics and the impacts of the evolution of drug resistance to address relevant biological questions with the following Specific Aims: AIM1: Defining HIV polyproteins and their components in retroviral assembly and maturation AIM 2: Determining HIV-host interactions driving virus reverse transcription and integration AIM 3: Understanding evolution of antiviral resistance mutations and their biological and biophysical implications through studies AIM 4: Developing and characterizing novel small molecule probes to understand biological function
HIV病毒进化中的相互作用(HIVE)中心在四年多前聚集在一起, 在原子、生物物理和进化水平上,理解相互作用的艾滋病毒的系统相互依赖性 大分子和它们的组合体塑造了艾滋病毒的生命周期。为了实现这一目标, 该计划将继续探索HIV Gag和Gag-Pol多聚蛋白的结构和生物物理相互作用, 衣壳,逆转录酶和整合酶及其进化关系。中心的研究重点 也将延伸到细胞因子,这些细胞因子反向告知事件的结构和大分子动力学 转录、组装和整合。这将包括关于APOBEC 3蛋白如何抑制逆转录病毒的研究。 转录,以及LEDGF在引导病毒整合中的作用及其对潜伏期的贡献, CPSF 6。对艾滋病毒耐药性的研究将结合遗传和结构的观点,基于突变, 由于蛋白质结构稳定性和功能的限制, 健身该计划的计算强度的深度集中在扩展结构,生物物理, 和病毒测序结果,用于开发预测结构模型和小分子探针靶向 病毒功能该中心的生物和计算研究的实力将提供深入了解 病毒和宿主机制的相互关系,使发现新的药物靶点和治疗 这些策略最终可能会导致治愈。蜂巢中心由一群高度合作的 研究人员在艾滋病毒研究方面有着丰富的经验,在结构、生物物理、 生物化学、计算生物学、合成化学和病毒学。他们将研究 病毒和病毒-宿主大分子相互作用的机制影响,沿着动力学和 耐药性演变的影响,以解决相关的生物学问题,具体如下 目的: AIM 1:定义HIV多聚蛋白及其在逆转录病毒装配和成熟中的组分 目的2:确定驱动病毒逆转录和整合的HIV-宿主相互作用 目的3:了解抗病毒耐药突变的演变及其生物学和生物物理学 研究的影响 目的4:开发和表征新型小分子探针以了解生物学功能

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Stefan G Sarafianos其他文献

Biochemical mechanism of clinical resistance to rilpivirine
  • DOI:
    10.1186/1471-2334-12-s1-p94
  • 发表时间:
    2012-05-04
  • 期刊:
  • 影响因子:
    3.000
  • 作者:
    Kamalendra Singh;Devendra K Rai;Bechan Sharma;Eleftherios Michailidis;Emily M Ryan;Kayla B Matzek;Maxwell D Leslie;Ariel N Hagedorn;Hong-Tao Xu;Mark A Wainberg;Bruno Marchand;Stefan G Sarafianos
  • 通讯作者:
    Stefan G Sarafianos
The Combination of 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine with Rilpivirine Shows Synergistic Anti-HIV-1 Activ- ity In Vitro
4-乙炔基-2-氟-2-脱氧腺苷与利匹韦林的组合在体外显示出协同抗 HIV-1 活性
  • DOI:
  • 发表时间:
    2012
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Atsuko Hachiya;Bruno Marchand;Eleftherios Michailidis;Eiichi N Kodama;Michael A Parni- ak;Hiroaki Mitsuya;Shinichi Oka;Stefan G Sarafianos
  • 通讯作者:
    Stefan G Sarafianos

Stefan G Sarafianos的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Stefan G Sarafianos', 18)}}的其他基金

Discovery of SARS-CoV-2 antivirals using a replicon assay
使用复制子测定发现 SARS-CoV-2 抗病毒药物
  • 批准号:
    10522048
  • 财政年份:
    2022
  • 资助金额:
    $ 531.78万
  • 项目类别:
Discovery of SARS-CoV-2 antivirals using a replicon assay
使用复制子测定发现 SARS-CoV-2 抗病毒药物
  • 批准号:
    10673119
  • 财政年份:
    2022
  • 资助金额:
    $ 531.78万
  • 项目类别:
Behavior of HIV in Viral Environments (B-HIVE)
HIV 在病毒环境中的行为 (B-HIVE)
  • 批准号:
    10650864
  • 财政年份:
    2022
  • 资助金额:
    $ 531.78万
  • 项目类别:
Dynamics of HIV Core Interactions
HIV核心相互作用的动态
  • 批准号:
    10650881
  • 财政年份:
    2022
  • 资助金额:
    $ 531.78万
  • 项目类别:
Dynamics of HIV Core Interactions
HIV核心相互作用的动态
  • 批准号:
    10508450
  • 财政年份:
    2022
  • 资助金额:
    $ 531.78万
  • 项目类别:
Behavior of HIV in Viral Environments (B-HIVE)
HIV 在病毒环境中的行为 (B-HIVE)
  • 批准号:
    10508443
  • 财政年份:
    2022
  • 资助金额:
    $ 531.78万
  • 项目类别:
Taking aim at HBV eradication using novel NRTIs and Capsid effectors
使用新型 NRTI 和衣壳效应物消灭 HBV
  • 批准号:
    9918244
  • 财政年份:
    2017
  • 资助金额:
    $ 531.78万
  • 项目类别:
Ultrapotent Inhibitors of Wild-type and Multi-drug Resistant HIV
野生型和多重耐药艾滋病毒的超强抑制剂
  • 批准号:
    9605989
  • 财政年份:
    2017
  • 资助金额:
    $ 531.78万
  • 项目类别:
Taking aim at HBV eradication using novel NRTIs and Capsid effectors
使用新型 NRTI 和衣壳效应物消灭 HBV
  • 批准号:
    9605893
  • 财政年份:
    2017
  • 资助金额:
    $ 531.78万
  • 项目类别:
Reverse Transcriptase Multi-Class Drug Resistance and Rilpivirine Susceptibility in Diverse HIV-1 Subtypes
不同 HIV-1 亚型中的逆转录酶多类耐药性和利匹韦林敏感性
  • 批准号:
    9140626
  • 财政年份:
    2016
  • 资助金额:
    $ 531.78万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 531.78万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 531.78万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 531.78万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 531.78万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 531.78万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 531.78万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 531.78万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 531.78万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 531.78万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 531.78万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了